Larimar Therapeutics Announces Proposed Underwritten Public Offering

Core Viewpoint - Larimar Therapeutics, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, aiming to raise capital for the development of its lead compound, nomlabofusp, and other pipeline candidates [1][2]. Group 1: Offering Details - The public offering includes an option for underwriters to purchase an additional 15% of the securities at the public offering price [1]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or the final terms [1][3]. - The offering is made under a shelf registration statement that was declared effective by the SEC on May 24, 2024 [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to support the development of nomlabofusp, other pipeline candidates, and for general corporate purposes, including research and development expenses [2]. Group 3: Company Overview - Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with nomlabofusp being developed for Friedreich's ataxia [5]. - The company plans to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases [5].